AGN-241622

· AbbVie

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AGN-241622, covering 2024-02-06 to 2024-02-06. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia [Phase 1, Phase 2]